The impact of COVID-19 pandemic on bronchiolitis (lower respiratory tract infection) due to respiratory syncytial virus: A systematic review and meta-analysis

Sasidharanpillai Sabeena[1*], Nagaraja Ravishankar[2], S Robin[3], Sabitha Sasidharan Pillai[4]

[1] Independent Researcher, Lalitpur, Bagmati Province, Kathmandu, Nepal

[2] Department of Biostatistics, Vallabhbhai Patel Chest Institute, University of Delhi, India

[3] Manipal Institute of Virology, Manipal Academy of Higher Education, Karnataka, India

[4] Paediatric Endocrinology Fellow, Warren Alpert Medical School of Brown University, 593 Eddy Street, Providence, RI 02903, USA

Abstract

Objective

This systematic review and meta-analysis aimed to quantitatively evaluate the effect of the COVID-19 pandemic on respiratory syncytial virus (RSV) associated bronchiolitis among hospitalised infants.

Methods

The study protocol was registered in the PROSPERO database (CRD42022314000) and was designed based on PRISMA guidelines updated in May 2020. The meta-analysis component was modified appropriately to synthesise the pooled proportion of infants having RSV-associated bronchiolitis before the COVID-19 pandemic in 2019 and during the pandemic with 95% confidence interval (CI).

Results:

The eight qualified studies for the meta-analysis were from Spain, Italy, France and China, including 109,186 symptomatic cases of bronchiolitis before the pandemic in 2019 and 61,982 cases in 2020-2021. The quantitative analysis included laboratory-confirmed RSV infection in 7691 infants with bronchiolitis reported before the pandemic in 2019. Meanwhile, during the pandemic, 4964 cases were associated with RSV infection. The pooled proportion of RSV-associated bronchiolitis cases before the pandemic in 2019 was 16.74% (95% CI 11.73-22.43%). The pooled proportion of confirmed RSV cases during the pandemic in 2020/2021 was 19.20 % (95% CI 12.01-27.59%).

Conclusion

There was an increase in RSV activity after the relaxation of stringent public health measures during the COVID-19 pandemic.

Keywords: bronchiolitis, COVID-19, pandemic, respiratory syncytial virus, SARS-CoV-2

- **What is already known on this topic**

The epidemiology of RSV infection which accounts for most bronchiolitis and viral pneumonias in infants was changed during the COVID-19 pandemic. During the spring or summer seasons, a resurgence in RSV positivity among bronchiolitis cases was noted globally during the COVID-19 pandemic.

- **What this study adds**

In spite of reporting lower number of bronchiolitis cases, more number of RSV associated bronchiolitis cases were detected among infants during the COVID-19 pandemic. Meanwhile, countries perceiving a very low number of RSV cases are at an increased risk of resurgence of RSV activity, mainly among older RSV-naïve children.

- **How this study might affect research, practice or policy**

Monitoring the effect of COVID-19 on RSV activity in infants is essential and regular sentinel surveillance of RSV must be carried out along with influenza and SARS-CoV-2 viruses to minimise the burden of hospitalisation and mortality. Health care professionals and hospitals must be prepared to tackle the rising number of paediatric RSV cases throughout the year. This review also emphasises the importance of promoting RSV maternal vaccines and passive childhood immunisation with monoclonal antibodies (mAbs).

- **Policy implications**

Policy makers from low-income countries have to ensure regular surveillance of RSV-associated bronchiolitis as these regions report the highest number of morbidity and mortality among infants. Even during challenging times of the pandemics and epidemics, monitoring has to be sustained.

The impact of COVID-19 pandemic on bronchiolitis (lower respiratory tract infection) due to respiratory syncytial virus: A systematic review and meta-analysis

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly infectious novel coronavirus that emerged in late 2019, leading to the coronavirus disease 2019 (COVID-19) pandemic. The non-pharmaceutical interventions such as masking, use of hand sanitisers and various public health measures of lockdowns, travel restrictions, social distancing, isolation, and quarantines helped to control the transmission in the initial months. Compared to the pre-pandemic seasons, the epidemiology of other common viral respiratory infections was significantly affected during the pandemic[1]. There was a decrease in respiratory viral infections, including respiratory syncytial virus (RSV), due to various non-pharmaceutical interventions implemented to curb the pandemic. These public health measures reduced the transmission of enveloped viruses such as influenza and (RSV)[2]. Lower respiratory tract infections or bronchiolitis in infants lead to increased hospitalisations and mortality during the winter season. The primary aetiology of bronchiolitis is infection by RSV, which results in recurrent wheeze and asthma in childhood[3]. Most of the bronchiolitis cases occur in low-income countries with limited RSV surveillance, which demands molecular diagnostic facilities. Over the past year, not a single RSV case was reported in many countries during the winter season, which extended between the last months of 2020 and early 2021. Many developed countries in the northern and southern hemispheres reported an unexpected surge in the RSV cases during the summer of 2021[4].

COVID-19 pandemic has led to alterations in the epidemiology of RSV infection which accounts for most bronchiolitis and viral pneumonias in infants. During the spring or summer seasons, a resurgence in areas reporting a meagre number of RSV cases was noted globally during the pandemic. Monitoring the effect of COVID-19 on the circulation of RSV infection

in infants is essential as there are no specific vaccines or antivirals for this virus. This systematic review and meta-analysis aimed to analyse the effect of the COVID-19 pandemic on RSV-associated bronchiolitis among hospitalised infants.

Methods

This systematic review was commenced after excluding registered or ongoing systematic reviews regarding the impact of the COVID-19 pandemic on bronchiolitis (lower respiratory tract infection) due to respiratory syncytial virus in the PROSPERO database. The study protocol was registered in the PROSPERO database (CRD42022314000) and can be accessed at https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022314000.

The systematic review and meta-analysis were performed based on the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines updated in May 2020[5]. The meta-analysis component was modified appropriately to synthesise the pooled proportion of paediatric bronchiolitis cases tested positive for RSV before the COVID-19 pandemic in 2019 and during the pandemic.

Description of the condition

Bronchiolitis: Bronchiolitis is the most common lower respiratory tract viral infection caused by RSV among children below two years[6], followed by rhinovirus and human Boca virus. The main clinical features of bronchiolitis are cough, chest recession or tachypnoea, crackles on chest auscultation or the first episode of acute wheeze[7].

Extended severe acute respiratory infection (SARI) due to RSV: Symptoms of cough/shortness of breath within the last ten days necessitating hospitalisation due to RSV is defined as extended severe respiratory infection due to RSV[8].

RSV infection: RSV infection was confirmed in symptomatic cases by real-time reverse transcription polymerase chain reaction (RT-PCR), immunofluorescence assay or virus isolation.

2 Study Protocol

An electronic search of PubMed/MEDLINE, Scopus and Google Scholar was carried out for all the articles in English published between January 2020 and March 2022 regarding the impact of the COVID-19 pandemic on bronchiolitis or lower respiratory tract infection due to the respiratory syncytial virus using search terms such as "impact" AND "COVID-19" OR "SARS-CoV-2" AND "RSV" NOT "vaccines". A manual library search for articles published in peer-reviewed journals was carried out. The references of retrieved articles were examined to increase the search sensitivity.

3 Inclusion process and criteria

Observational studies in English reporting the number of immunocompetent paediatric cases aged two years or below having bronchiolitis or lower respiratory tract infection due to RSV infection were included. Conference abstracts and commentaries were excluded. The studies reporting the data among older children and adults were eliminated. The articles reporting the RSV activity among immunocompromised cases were also not considered.

4 Data extraction

A validated proforma detailing the name of the first author, year of publication, study area, number of cases with bronchiolitis/lower respiratory tract infection (LRTI) attended the hospitals in 2019 and during the pandemic, number of laboratory-confirmed RSV positive cases in 2019 and during the pandemic was prepared. A three-stage selection of published articles was carried out for the final inclusion. One reviewer evaluated the titles of the records for the relevance for inclusion in the study (n=5479). Studies applicable for the review were

moved to the second stage after eliminating irrelevant topics and duplicates (n=5290). In the second stage, the abstracts of the studies were obtained and were independently examined by two reviewers (n=97). After reviewing the abstracts, full texts of studies were procured, which were inspected by two reviewers independently (n=50). The corresponding authors were communicated electronically if further clarification was needed. Manual library searches for articles in peer-reviewed journals were carried out, and references of retrieved articles were reviewed to increase the search sensitivity. The PRISMA 2020 flow diagram[5] (**Fig. 1**) depicts the study selection process. The last date of the search was on March 22, 2022.

5 Risk of bias (quality) assessment in individual studies

To assess the risk of bias in individual studies (quality assessment), chosen after the abstract and content review, the National Institutes of Health checklist for observational, cohort and cross-sectional studies was used[9]. The studies with a minimum score of eight or above, seven, or five or less than five "Yes responses" were considered good, fair, and poor quality, respectively. For cross-sectional studies, question numbers 1, 2, 3, 4, 5 and 11 were applicable. The responses to the remaining eight questions (6-10, 12, 13, 14) were not applicable (NA). The studies with six "Yes" responses were considered good, and those with four /five were taken as fair. The studies with less than four "Yes responses" were considered poor quality. The quality of the studies was evaluated by two reviewers independently.

6 Statistical analysis

The meta-analysis was accomplished in STATA version 13.0 (College Station, Texas 77, 845 USA). The forest plots were constructed using metaprop package in STATA. The pooled proportion of symptomatic cases of RSV-associated bronchiolitis or lower respiratory tract infections before the pandemic in 2019 and during the pandemic was reported with 95% CI. Chi-square statistic (Q statistic) and I^2 index to quantify the heterogeneity was noted as

considerable heterogeneity across the studies was expected. The I^2 value ranging between 0% to 24% specifies consistency. I^2 values of 25%-49% imply low heterogeneity and 50-74% points toward moderate heterogeneity. The I^2 value varying between 75%-100% is indicative of high heterogeneity[10].

7 Assessment of Publication bias

Egger's test was used to report the publication bias. Weighted linear regression with standardised effect estimate and precision was considered the dependent and independent variables, respectively. In the present study, the $\log_e$ proportion of RSV positive bronchiolitis cases and precision were considered the effect estimate and 1/standard error of $\log_e$ proportion rate, respectively. Weights were allotted using the inverse variance approach (1/variance of the effect estimate). A statistically significant bias coefficient is the evidence for publication bias.

Results

Included studies

The eight qualified studies for the meta-analysis were from Spain, Italy, France and China, including 109,186 symptomatic cases of bronchiolitis before the pandemic in 2019 and 61,982 cases during the pandemic[11–18]. All these studies were qualified, as good as shown in **Table 1**. These studies reported 7691 laboratory-confirmed RSV associated lower respiratory tract infections in 2019 and 4964 during the pandemic in 2020/21. Two studies from Spain and France were multicentric[16,18]. The highest number of symptomatic cases were admitted in the multicentric study from Spain[16] before the pandemic in 2019 and during the pandemic. All the studies chosen for the meta-analysis reported a decrease in bronchiolitis cases with increased RSV positivity during the pandemic. The highest RSV

positivity in bronchiolitis was 70.2% before the pandemic. Meanwhile, during the COVID-19 pandemic, RSV was the causative agent in up to 77.8% of bronchiolitis cases, as in Table 1.

Meta-analysis

The pooled proportion of RSV-associated bronchiolitis cases before the pandemic in 2019 was 16.74% (95% CI 11.73%-22.43%) as in **Fig.2**. **Fig. 3** represents the pooled proportion of RSV cases among infants during the pandemic in 2020/2021, as 19.20% (95% CI 12.01%-27.59%). As the I^{2-}value was>90%, high heterogeneity was observed between the studies.

Publication bias

As shown in **Table 2,** the *p*-value for the bias coefficient was not statistically significant. Hence there was no publication bias.

Discussion

The studies qualified for this meta-analysis were from China and Europe. The pooled proportion of RSV positivity in bronchiolitis cases was more during the COVID-19 pandemic, even though a decline in bronchiolitis cases or lower respiratory tract infections was observed during the COVID-19 pandemic.

Many countries such as Italy, Germany, Belgium, Vienna and Brazil reported no hospitalised bronchiolitis cases during the winter season[12,19–21]. Similarly, the study from Israel reported a temporal shift of RSV epidemic to spring season from winter[22]. During the COVID-19 pandemic, hospitals in Spain reported a steep decline in bronchiolitis cases and RSV positivity with seven months delayed RSV peak in July 2021[16]. Meanwhile, France

reported a rise in RSV cases during the late winter months of 2021 after the second national lockdown in December 2020 [15]. Japan observed no reporting of RSV cases in 2020, followed by a resurgence in July 2021[23]. The tropical country of Thailand, located in South East Asia, witnessed a delayed RSV season in 2020 among children with influenza-like illness[24]. There was an increase in the number of confirmed RSV cases across all age groups during the spring season of the year 2020 in Australia and South Africa[25,26]. The inter-seasonal rise in RSV infections during the summer was observed in the northern and southern hemispheres[27,28]. Italy reported a significant decline in hospitalised cases of bronchiolitis in 2020, with no bronchiolitis cases in 2021. However, a late RSV peak was not observed in Italy, unlike many countries[12]. In 2020, China reported a decrease in lower respiratory tract infection among children, mainly due to the strict public health measures to contain the SARS-CoV-2 infection. The studies from Shanghai and Xiamen reported a decline in RSV activity among the hospitalised children. Both the studies observed a mild increase in RSV and influenza activity during the winter months without a temporal shift in seasonality[14,29]. However, another single centre study from Hangzhou reported a marked rise in RSV cases during the winter season of 2020, comparable to the pre-pandemic period[17].

Respiratory viral infections at young age facilitate the building up of trained immunity. Apart from a relatively young population of Africa compared to other parts of the world, prior exposure to other cross-reactive viruses is another causative factor for low SARS-CoV-2 related morbidity and mortality in Sub-Saharan Africa[30]. However, countries perceiving a very low number of RSV cases are at an increased risk of resurgence of RSV infection, mainly among older RSV-naïve children[31]. Sentinel surveillance of RSV is better in many European countries than in other parts of the world[32,33]. There is no data regarding the

RSV activity from the majority of the Asian and African countries having higher RSV associated disease burden [34].

Causes of heterogeneity

The main heterogeneity was in the number of bronchiolitis cases enrolled before and during the pandemic. Two multicentric studies enrolled a higher number of hospitalised cases compared to single centre studies. Even though six studies confirmed RSV infection by RT-PCR, two studies from China detected the RSV infection by direct immunofluorescence assay, which is less sensitive[35]. Another disparity was in the time of the year during which the samples were procured from paediatric bronchiolitis cases. Although six studies enrolled infants below one year, two studies incorporated cases below two years.

Limitation

Before the COVID-19 pandemic, there was no routine testing of bronchiolitis samples for RSV from developing countries in South East Asia, Africa and Latin America. All the studies included in the meta-analysis were from Europe and China. Even though there were studies from other parts of the world reporting low RSV activity among infants during the COVID-19 pandemic, very few studies reported RSV positivity before the pandemic.

During the coming seasons, health care professionals and hospitals must be prepared to manage the increasing number of symptomatic RSV cases. This review emphasises the importance of promoting RSV maternal vaccines and passive childhood immunisation with monoclonal antibodies (mAbs).

Conclusion

There was an increase in RSV activity after relaxing stringent public health measures during the COVID-19 pandemic in the northern and southern hemispheres. Efforts for the diagnosis

and surveillance for RSV must be reinforced along with influenza and SARS-CoV-2 viruses to minimise the burden of hospitalisation and mortality among infants.

Funding: This study was not funded

Conflicts of interest: All authors report no conflicts of interest

ETHICS STATEMENT

The authors state that this manuscript does not involve any misconduct such as plagiarism, forgery, tampering, improper signature, multiple submission, repeated publication, split publication, etc. The systematic review and meta analysis used published data in indexed journals. Ethical approval to conduct the analysis was not sought as this was a secondary data analysis that requires no approval. No data with a personal identifier was used.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request (Dr Sasidharanpillai Sabeena, sabeenauthradam@gmail.com).

References

1 Britton PN, Hu N, Saravanos G, *et al.* COVID-19 public health measures and respiratory syncytial virus. *Lancet Child Adolesc Health* 2020;**4**:e42–3. doi:10.1016/S2352-4642(20)30307-2

2 Takashita E, Kawakami C, Momoki T, *et al.* Increased risk of rhinovirus infection in children during the coronavirus disease-19 pandemic. *Influenza Other Respir Viruses* 2021;**15**:488–94. doi:10.1111/irv.12854

3 Blanken MO, Rovers MM, Molenaar JM, *et al.* Respiratory Syncytial Virus and Recurrent Wheeze in Healthy Preterm Infants. *New England Journal of Medicine* 2013;**368**:1791–9. doi:10.1056/NEJMoa1211917

4 Williams TC, Sinha I, Barr IG, *et al.* Transmission of paediatric respiratory syncytial virus and influenza in the wake of the COVID-19 pandemic. *Eurosurveillance* 2021;**26**:2100186. doi:10.2807/1560-7917.ES.2021.26.29.2100186

5 Page MJ, McKenzie JE, Bossuyt PM, *et al.* The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;**372**:n71. doi:10.1136/bmj.n71

6 Kenmoe S, Kengne-Nde C, Ebogo-Belobo JT, *et al.* Systematic review and meta-analysis of the prevalence of common respiratory viruses in children < 2 years with bronchiolitis in the pre-COVID-19 pandemic era. *PLOS ONE* 2020;**15**:e0242302. doi:10.1371/journal.pone.0242302

7 NICE. *Bronchiolitis in children: diagnosis and management*. London: : National Institute for Health and Care Excellence (NICE) 2021. http://www.ncbi.nlm.nih.gov/books/NBK573086/ (accessed 3 Mar 2022).

8 WHO. Case definitions. https://www.who.int/teams/control-of-neglected-tropical-diseases/yaws/diagnosis-and-treatment/global-influenza-programme (accessed 7 Dec 2021).

9 Study Quality Assessment Tools | NHLBI, NIH. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools (accessed 27 Sep 2020).

10 Higgins JPT, Thompson SG, Deeks JJ, *et al.* Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**:557–60. doi:10.1136/bmj.327.7414.557

11 Guitart C, Bobillo-Perez S, Alejandre C, *et al.* Bronchiolitis, epidemiological changes during the SARS-CoV-2 pandemic. *BMC Infectious Diseases* 2022;**22**:84. doi:10.1186/s12879-022-07041-x

12 Stera G, Pierantoni L, Masetti R, *et al.* Impact of SARS-CoV-2 Pandemic on Bronchiolitis Hospitalizations: The Experience of an Italian Tertiary Center. *Children (Basel)* 2021;**8**:556. doi:10.3390/children8070556

13 Curatola A, Lazzareschi I, Bersani G, *et al.* Impact of COVID-19 outbreak in acute bronchiolitis: Lesson from a tertiary Italian Emergency Department. *Pediatr Pulmonol* 2021;**56**:2484–8. doi:10.1002/ppul.25442

14 Liu P, Xu M, Cao L, *et al.* Impact of COVID-19 pandemic on the prevalence of respiratory viruses in children with lower respiratory tract infections in China. *Virol J* 2021;**18**:159. doi:10.1186/s12985-021-01627-8

15 Fourgeaud J, Toubiana J, Chappuy H, *et al.* Impact of public health measures on the post-COVID-19 respiratory syncytial virus epidemics in France. *Eur J Clin Microbiol Infect Dis* 2021;**40**:2389–95. doi:10.1007/s10096-021-04323-1

16 Torres-Fernandez D, Casellas A, Mellado MJ, *et al.* Acute bronchiolitis and respiratory syncytial virus seasonal transmission during the COVID-19 pandemic in Spain: A national perspective from the pediatric Spanish Society (AEP). *J Clin Virol* 2021;**145**:105027. doi:10.1016/j.jcv.2021.105027

17 Ye Q, Liu H. Impact of non-pharmaceutical interventions during the COVID-19 pandemic on common childhood respiratory viruses - An epidemiological study based on hospital data. *Microbes Infect* 2022;**24**:104911. doi:10.1016/j.micinf.2021.104911

18 Casalegno J-S, Ploin D, Cantais A, *et al.* Characteristics of the delayed respiratory syncytial virus epidemic, 2020/2021, Rhône Loire, France. *Eurosurveillance* 2021;**26**:2100630. doi:10.2807/1560-7917.ES.2021.26.29.2100630

19 Diesner-Treiber SC, Voitl P, Voitl JJM, *et al.* Respiratory Infections in Children During a Covid-19 Pandemic Winter. *Front Pediatr* 2021;**9**:740785. doi:10.3389/fped.2021.740785

20 Van Brusselen D, De Troeyer K, Ter Haar E, *et al.* Bronchiolitis in COVID-19 times: a nearly absent disease? *Eur J Pediatr* 2021;**180**:1969–73. doi:10.1007/s00431-021-03968-6

21 Varela FH, Scotta MC, Polese-Bonatto M, *et al.* Absence of detection of RSV and influenza during the COVID-19 pandemic in a Brazilian cohort: Likely role of lower transmission in the community. *J Glob Health* 2021;**11**:05007. doi:10.7189/jogh.11.05007

22 Weinberger Opek M, Yeshayahu Y, Glatman-Freedman A, *et al.* Delayed respiratory syncytial virus epidemic in children after relaxation of COVID-19 physical distancing measures, Ashdod, Israel, 2021. *Euro Surveill* 2021;**26**. doi:10.2807/1560-7917.ES.2021.26.29.2100706

23 Ujiie M, Tsuzuki S, Nakamoto T, *et al.* Resurgence of Respiratory Syncytial Virus Infections during COVID-19 Pandemic, Tokyo, Japan. *Emerg Infect Dis* 2021;**27**:2969–70. doi:10.3201/eid2711.211565

24 Thongpan I, Vichaiwattana P, Vongpunsawad S, *et al.* Upsurge of human rhinovirus infection followed by a delayed seasonal respiratory syncytial virus infection in Thai children during the coronavirus pandemic. *Influenza and Other Respiratory Viruses* 2021;**15**:711–20. doi:10.1111/irv.12893

25 Zheng Z, Pitzer VE, Shapiro ED, *et al.* Estimation of the Timing and Intensity of Reemergence of Respiratory Syncytial Virus Following the COVID-19 Pandemic in the US. *JAMA Netw Open* 2021;**4**:e2141779. doi:10.1001/jamanetworkopen.2021.41779

26 Tempia S, Walaza S, Bhiman JN, *et al.* Decline of influenza and respiratory syncytial virus detection in facility-based surveillance during the COVID-19 pandemic, South Africa, January to October 2020. *Euro Surveill* 2021;**26**. doi:10.2807/1560-7917.ES.2021.26.29.2001600

27 Saravanos GL, Hu N, Homaira N, *et al.* RSV Epidemiology in Australia Before and During COVID-19. *Pediatrics* 2022;**149**:e2021053537. doi:10.1542/peds.2021-053537

28 Respiratory Syncytial Virus (RSV) in Florida | Florida Department of Health. https://www.floridahealth.gov/diseases-and-conditions/respiratory-syncytial-virus/ (accessed 2 Mar 2022).

29 Wang J, Xiao T, Xiao F, *et al.* Time Distributions of Common Respiratory Pathogens Under the Spread of SARS-CoV-2 Among Children in Xiamen, China. *Front Pediatr* 2021;**9**:584874. doi:10.3389/fped.2021.584874

30 Njenga MK, Dawa J, Nanyingi M, *et al.* Why is There Low Morbidity and Mortality of COVID-19 in Africa? *The American Journal of Tropical Medicine and Hygiene* 2020;**103**:564–9. doi:10.4269/ajtmh.20-0474

31 Foley DA, Phuong LK, Peplinski J, *et al.* Examining the interseasonal resurgence of respiratory syncytial virus in Western Australia. *Arch Dis Child* 2022;**107**:e7. doi:10.1136/archdischild-2021-322507

32 Mollers M, Barnadas C, Broberg EK, *et al.* Current practices for respiratory syncytial virus surveillance across the EU/EEA Member States, 2017. *Euro Surveill* 2019;**24**:1900157. doi:10.2807/1560-7917.ES.2019.24.40.1900157

33 Teirlinck AC, Broberg EK, Berg AS, *et al.* Recommendations for respiratory syncytial virus surveillance at national level. *European Respiratory Journal* Published Online First: 1 January 2021. doi:10.1183/13993003.03766-2020

34 Broor S, Campbell H, Hirve S, *et al.* Leveraging the Global Influenza Surveillance and Response System for global respiratory syncytial virus surveillance-opportunities and challenges. *Influenza Other Respir Viruses* 2020;**14**:622–9. doi:10.1111/irv.12672

35 Shafik CF, Mohareb EW, Youssef FG. Comparison of Direct Fluorescence Assay and Real-Time RT-PCR as Diagnostics for Respiratory Syncytial Virus in Young Children. *Journal of Tropical Medicine* 2011;**2011**:e781919. doi:10.1155/2011/781919

Table 1: Characteristics of the studies qualified for the meta-analysis

S No	Reference (year)	Region	Study design	Study site	Age in months	LRTI/ bronchiolitis before the pandemic	Duration	RSV Positivity N(%)	LRTI/ bronchiolitis during the pandemic	Duration	RSV Positivity N (%)	Diagnosis	Quality of the study
1	Guitart et al 2022[11]	Barcelona Spain	Prospective observational	Single centre	<12	124	2019-20	87 (70.2)	63	2020-21	49 (77.8)	RT-PCR	Good
2	Stera et al[12] 2021	Bologna Italy	retrospective observational	Single centre	≤12	114	Oct 2018-April2019	75 (65.8)	98	2019/2020 Oct-April	72 (73.5)	RT-PCR	Good
3	Curatola et al 2021[13]	Rome Italy	retrospective observational	Single centre	≤24	238	2019 Feb-2020 Feb	40 (16.8)	33	2020 Feb-2021 Feb	6 (18.2)	RT-PCR	Good
4	Liu et al Aug 2021[14]	Shanghai China	retrospective observational	Single centre	≤12	4600	2019	304 (6.6)	2507	2020	114 (4.5)	Multiplex Direct IFA	Good
5	Fourgeaud et al 2021[15]	France	retrospective observational	Single centre	≤11	5396	Aug2019-July 2020	172 (3.2)	4804	2020/21-Aug-April	169 (3.5)	RT-PCR	Good
6	Torres-Fernandes et al 2021[16]	Spain	retrospective observational	multicentric	≤24	82,577	2019	5936 (7.2)	42,924	2020	3912 (9.1)	RT-PCR	Good
7	Ye et al[17]	Hangzhou China	retrospective observational	Single centre	≤12	7010	2019	953 (!3.6)	2825	2020	565 (20.0)	Multiplex Direct IFA	Good
8	Casalegno et al 2021[18]	Lyon France	retrospective observational	multicentric	≤12	9,127	2019/20 Sept-May	124 (1.35)	8,728	2020/21 Sept-May	77 (0.88)	RT-PCR	Good

Table 2: The table depicts the results of Egger's test for publication bias

Results of Egger's test (Before the Pandemic)		
Coefficient	Estimate (95%CI)	P-value
Slope	0.0532 (0.0067, 0.0997)	0.051
Bias	2.9071 (-2.5261,8.3403)	0.238
Results of Egger's test (after the Pandemic)		
Slope	0.0605 (-0.0093, 0.1304)	0.449
Bias	2.4388 (-3.7147,8.5924)	0.370



Fig.1: PRISMA 2020 flow diagram for updated systematic reviews which included searches of databases, registers and other source[5]. The flow diagram illustrates the number of studies identified, screened, abstracts/full-text articles included/excluded for the systematic review and meta-analysis.



Fig.2. The Forest Plot depicting the proportion of bronchiolitis cases tested positive for RSV before the COVID-19 pandemic using random effects model. Squares indicate the effect size of individual studies and the extended lines denote 95% confidence intervals (CI). Sizes of squares imply the weight of studies based on sample size using a random effects analysis. The diamond data indicates pooled prevalence. Test of heterogeneity: $I^{2=}$ 99.62%, *p*-value=0.00



Fig. 3 The Forest Plot illustrating the proportion of RSV positive bronchiolitis cases during the COVID-19 pandemic. Squares indicate the effect size of individual studies and the extended lines denote 95% confidence intervals (CI). Sizes of squares imply the weight of studies based on sample size using a random effects analysis. The diamond data indicates pooled prevalence. Test of heterogeneity: $I^{2=}$ 99.69 %, p=0.00.

Figure captions

Fig.1. PRISMA 2020 flow diagram for updated systematic reviews which included searches of databases, registers and other sources[5]. The flow diagram illustrates the number of studies identified, screened, abstracts/full-text articles included/excluded for the systematic review and meta-analysis.

Fig.2. The Forest Plot depicting the proportion of bronchiolitis cases tested positive for RSV before the COVID-19 pandemic using random effects model. Squares indicate the effect size of individual studies and the extended lines denote 95% confidence intervals (CI). Sizes of squares imply the weight of studies based on sample size using a random effects analysis. The diamond data indicates pooled prevalence. Test of heterogeneity: $I^{2=}$ 99.62%, *p*-value=0.00

Fig.3. The Forest Plot illustrating the proportion of RSV positive bronchiolitis cases during the COVID-19 pandemic using random effects model. Squares indicate the effect size of individual studies and the extended lines denote 95% confidence intervals (CI). Sizes of squares imply the weight of studies based on sample size using a random effects analysis. The diamond data indicates pooled prevalence. Test of heterogeneity: $I^{2=}$ 99.69 %, *p*=0.00.